EUVIMEDEUVIMED entdecken
Crossref

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia

Yuan Sun, Xu Wang, Wen-Min Chen, Yue Hao, Ling-Di Li, Jin-Ying Li, Kai Sun, Zong-Yan Shi, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Ya-Zhen Qin iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Yuan Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT mut ) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT mut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KIT mut (D816V/H/Y or N822K) were tested for KIT mut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT mut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT mut ‐high (KIT_H) group and the KIT mut ‐low (KIT_L) group. The KIT_H patients showed significantly lower relapse‐free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation ( p = 0.0040 and 0.021, respectively) and Course 2 consolidation ( p = 0.018 and 0.011, respectively) but not at diagnosis and CR. The 3‐log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteProto-Oncogene Proteins c-kitHumansCore Binding Factor Alpha 2 SubunitNeoplasm, ResidualPathologic Complete ResponsePrognosisRecurrenceRUNX1 Translocation Partner 1 ProteinTranslocation, Genetic

Stichwörter der Autor:innen

KIT mutant transcript levelsdigital PCRmeasurable residual diseaserelapset (8; 21) AML

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 ProteinRUNX1 protein, humanRUNX1T1 protein, humanKIT protein, humanProto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • Beijing Hightrust Diagnostics, Co., Ltd, Beijing, China.

ORCID-Profile: Ya-Zhen Qin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Sun, Y., Wang, X., Chen, W. M., Hao, Y., Li, L. D., Li, J. Y., Sun, K., Shi, Z. Y., Jiang, H., Jiang, Q., Huang, X. J., & Qin, Y. Z. (2024). Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. Hematological Oncology. https://doi.org/10.1002/hon.3264

Vancouver

Sun Y, Wang X, Chen WM, Hao Y, Li LD, Li JY, et al. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. Hematological Oncology. 2024. doi:10.1002/hon.3264

BibTeX
@article{Sun2024,
  author = {Sun, Yuan and Wang, Xu and Chen, Wen-Min and Hao, Yue and Li, Ling-Di and Li, Jin-Ying and Sun, Kai and Shi, Zong-Yan and Jiang, Hao and Jiang, Qian and Huang, Xiao-Jun and Qin, Ya-Zhen},
  title = {Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3264}
}
Kostenlos starten →